Trials / Completed
CompletedNCT01429064
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Safety and Tolerability of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Extension Study to Study 3104001
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ODM-201 | ODM-201 administered orally daily |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2011-09-05
- Last updated
- 2017-02-20
- Results posted
- 2016-12-22
Locations
17 sites across 6 countries: United States, Czechia, Estonia, Finland, France, United Kingdom
Source: ClinicalTrials.gov record NCT01429064. Inclusion in this directory is not an endorsement.